Strategic License Agreements - Additional Information (Details) $ in Thousands	1 Months Ended		3 Months Ended
	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($) € / shares $ / shares	Dec. 31, 2022 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 198	$ 1,362
Current deferred revenue			302			$ 517
Contract liabilities			2,643			2,696
Contract assets			$ 0			$ 0
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date			2021-03
Non refundable payment received					$ 21,500
Percentage of payment for cost incurred in PIP trial					50.00%
Additional upfront payment to be received					$ 122,100
Rate of revenue share					25.00%
Reimbursement	$ 3,000
Upfront payment					$ 21,500
Modified transaction price	25,100
Estimated amount incurred	$ 3,600
Allocation price net					12,000
Total deferred revenue			$ 2,600	2,800
Current deferred revenue			300	2,100
Immedica Pharma AB | PEACE Trial and BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price					9,600
Revenue recognized			$ 100	$ 1,400
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price					$ 3,500
Immedica Pharma AB | License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 12,000
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial					50.00%
Costs incurred in performing PIP the trial					$ 1,800
Milestone payments exchange rate | € / shares					1.00
Immedica Pharma AB | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments exchange rate | $ / shares					1.09